Starting April 2010, the name for Kapidex was officially changed to Dexilant™. The name was changed because it was too similar to the names of a few other drugs, leading to a few "mix-ups." Please see our Dexilant articles within eMedTV.com for current information about this medication.
The U.S. Food and Drug Administration (FDA) uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category B is given to medicines that have not been adequately studied in pregnant humans but do not appear to cause harm to the fetus in animal studies. Medications that have been shown to be safe for use in pregnancy in humans (but have caused problems in laboratory animals) are also given a Category B rating.
Although Kapidex has not been adequately studied in pregnant humans, studies in rabbits do not indicate that the drug is likely to cause any harm to a developing fetus.
However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category B medicine should be given to a pregnant woman only if the healthcare provider believes that the benefits to the pregnant woman outweigh any possible risks to the unborn child.